Dizal (Jiangsu) Pharmaceutical Co., Ltd (SHA: 688192), the China-based joint venture established by AstraZeneca (AZ, NASDAQ: AZN) and the state-backed Future Industry Investment Fund in October 2017, has announced plans to raise RMB 2.6 billion (USD 376.1 million) through a private placement of 40,815,137 shares. The funds raised will be allocated towards the research and development of novel drugs, the industrialization of world-class innovative drugs, and the supplementation of working capital.
Product Pipeline and Core Products
Dizal Pharma prides itself on a robust product pipeline that includes five innovative drugs under global clinical development for a variety of diseases. The company’s core product, sunvozertinib (DZD9008), is a next-generation epidermal growth factor receptor (EGFR) inhibitor. It is currently awaiting regulatory decisions in China, where it has been granted priority review status as of January this year. Another notable drug in the pipeline is golidocitinib (DZD4205), which is recognized as the world’s first and only highly selective JAK1 inhibitor in the global regulatory clinical stage for T cell lymphoma treatment. This drug is currently undergoing global multi-center Phase II clinical trials.
Fast-Track Approvals and Clinical Data Support
Both sunvozertinib and golidocitinib have received fast-track approvals in the United States and China, supported by positive Phase II single-arm clinical data, as per the company’s announcement. This underscores Dizal Pharma’s commitment to advancing cutting-edge treatments and its potential impact on the global pharmaceutical market.-Fineline Info & Tech
